Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company
GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that the board […]
English
Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion
Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress
GOTHENBURG, Sweden, September 29, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced a poster presentation
Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
GOTHENBURG, Sweden, September 12, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract
Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer
GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin
GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the outcome of
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a
Isofol Announces Election of Three New Board Members
GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced the election of
Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States
GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from